There’s a rapidly intensifying battle underway for Metsera, a three-year-old obesity startup working on experimental treatments in one of the hottest areas in medicine https://t.co/cK9b4OS7jU ...

Today's a big announcement for Americans who suffer from obesity, overweight. Um, you know, we know that these medicines we've invented like our Zepbound have had many uh breakthroughs preventing chronic disease, but they've been out of reach for too many people because of cost. We really need coverage, and today's announcement is about coverage for seniors.So, uh, we agreed with the Trump administration to enable coverage starting next spring for our medication and others, um, for $50 a month. That's a hug ...

So, good news for some of you, but what does it mean for Lily and Novo Nordis. Ask Jared Holtz. He is healthc care strategist at Mizuo.Jared, great news for for millions of people that have been struggling with with their weight for years. But what does it mean for these companies bottom lines. >> Hey, Brian, thanks for having me.I I think when I take a step back, it it's probably more positive than negative. I think investors have been thinking and sort of modeling negative price for this category for a wh ...

Metsera’s next-generation weight-loss drug showed good tolerability with few participants dropping out of a mid-stage trial, adding to the obesity company’s appeal as two industry giants fight over who will buy it https://t.co/8SLoMXCzlq ...

Key Products & Market Performance - Tzepide and Mjaro (Zepbound) achieved market leadership in the US for both diabetes and obesity, driven by strong international performance [2] - Mangaro rollout in China, Brazil, and India indicates strong global demand [3] - Oral pill orforglipron is completing Phase 3 program with submission in Q4, aiming for broad global rollout [4][6] Pipeline & Clinical Trials - Oral pill offers a less intrusive alternative to injections, potentially appealing to those reaching their weight target [8] - Retatrutide, a triple-acting agent, shows promise for even greater weight loss than Zepbound or Mounjaro, with initial study focused on knee pain [10] - Studies are exploring the effects of weight loss drugs on inflammation, chronic knee pain, and addictive properties in the brain [11][12] Strategic Outlook - The company anticipates continued FDA approvals, supported by user fees, despite potential government shutdowns [7] - The company has built a head inventory to introduce orforglipron around the world [8] - The company is exploring additional indications beyond weight loss, such as knee pain and back pain, targeting a larger patient population [9][10]

- So we've each had our copious amount of coffee just before coming on, and I feel like it's appropriate to ask you based on the body of your work, what you had for breakfast. - Coffee. - Coffee.All right, well, you know, CEOs take note. You heard it from Marion Nestle herself. - I'm not a breakfast eater.- Oh my goodness. We're gonna have to come back to that 'cause that feels significant. Let's get started with, you know, the other news of the day, which is, you know, the final version of Secretary Kenned ...

Ozempic and other weight-loss drugs may be a promising solution to the growing problem of obesity, but they’ve got a surprising foe: fat activists. https://t.co/Y8Qi1GIZQr ...

Industry Trend - Weight-loss drugs like Ozempic are seen as a potential solution to obesity [1] Social Impact - Fat activists are posing a challenge to the use of weight-loss drugs [1]

Ozempic and other weight-loss drugs may be a promising solution to the growing problem of obesity, but they’ve got a surprising foe: fat activists. https://t.co/wdC7XHm73J ...

“Even if every person living with obesity took medicines, we couldn’t treat our way out of this crisis,” warns Lars Fruergaard Jørgensen. In a guest essay he argues that “the world must prioritise prevention” https://t.co/W27aUCTPmDIllustration: Dan Williams https://t.co/TW0zerNZjd ...